Compare Repligen Corporation Common Stock (RGEN) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vanguard Value Index Fund ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Vanguard Value Index Fund ETF trades at $221.56 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 23.6× Repligen Corporation Common Stock's market cap, and Vanguard Value Index Fund ETF is more actively traded (1,774,364 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vanguard Value Index Fund ETF for 143 Days on average.
| RGEN | VTV | |
|---|---|---|
Market Cap | $11.14B | $262.40B |
Volume | 1,259,263 | 1,774,364 |
Sector | Health | — |
52-Week High | $194.57 | $227.51 |
52-Week Low | $102.87 | $182.89 |
Typical Hold Time | 0 Days | 143 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VTV trades at $221.14, down 0.13% on the day, with a bullish technical signal from moving averages but overbought RSI levels. The ETF offers a 2.3% dividend yield and has attracted institutional inflows, with recent news highlighting its outperformance versus growth funds in 2026. Value stocks are gaining favor amid market rotation away from tech concentration.
Outlook remains positive given value's momentum and institutional interest, though risks include prolonged underperformance versus growth and fee-related long-term tracking differences. The ETF provides stable income and diversification but faces competition from broader market funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
